MBX Biosciences, Inc. Proceeds from Issuance of Convertible Preferred Stock
MBX Biosciences, Inc. (MBX) reported Proceeds from Issuance of Convertible Preferred Stock of $63.50 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2025-11-06
- 2024-09-30: Proceeds from Issuance of Convertible Preferred Stock 9 month $63.50M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 9 month |
|---|---|
| 2024-09-30 | $63.50M 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |